{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:32:30Z","timestamp":1793521950801,"version":"4.5.0"},"reference-count":68,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2010,8,23]],"date-time":"2010-08-23T00:00:00Z","timestamp":1282521600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0012300","type":"journal-article","created":{"date-parts":[[2010,8,23]],"date-time":"2010-08-23T20:44:27Z","timestamp":1282596267000},"page":"e12300","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Optimizing Combination Therapies with Existing and Future CML Drugs"],"prefix":"10.1371","volume":"5","author":[{"given":"Allen A.","family":"Katouli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia L.","family":"Komarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2010,8,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.","volume":"108","author":"HA Bradeen","year":"2006","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1073\/pnas.0800587105","article-title":"SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.","volume":"105","author":"T O'Hare","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis.","volume":"103","author":"B Calabretta","year":"2004","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/asheducation-2003.1.132","article-title":"Chronic myeloid leukemia.","author":"JV Melo","year":"2003","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.leu.2402577","article-title":"Chronic myelogenous leukemia: mechanisms underlying disease progression.","volume":"16","author":"AS Shet","year":"2002","journal-title":"Leukemia"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1532\/IJH97.04032","article-title":"Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.","volume":"79","author":"C Yoshida","year":"2004","journal-title":"Int J Hematol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1002\/cncr.11316","article-title":"Trends in leukemia incidence and survival in the United States (1973\u20131998).","volume":"97","author":"Y Xie","year":"2003","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood.V70.4.905.905","article-title":"Radiogenic leukemia revisited.","volume":"70","author":"WC Moloney","year":"1987","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","article-title":"Practical management of patients with chronic myeloid leukemia receiving imatinib.","volume":"21","author":"MW Deininger","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1080\/10428190410001723278","article-title":"Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib.","volume":"45","author":"M Loriaux","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nrd1579","article-title":"Strategies to overcome resistance to targeted protein kinase inhibitors.","volume":"3","author":"H Daub","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"ref12","first-page":"225","article-title":"Overcoming resistance to imatinib by combining targeted agents.","volume":"2","author":"BJ Druker","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(04)91001-9","article-title":"Imatinib as a paradigm of targeted therapies.","volume":"91","author":"BJ Druker","year":"2004","journal-title":"Adv Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.","volume":"4","author":"CB Gambacorti-Passerini","year":"2003","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00062752-200401000-00006","article-title":"Mechanisms and implications of imatinib resistance mutations in BCR-ABL.","volume":"11","author":"V Nardi","year":"2004","journal-title":"Curr Opin Hematol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1535-6108(02)00101-0","article-title":"Resistance in the land of molecular cancer therapeutics.","volume":"2","author":"KM Shannon","year":"2002","journal-title":"Cancer Cell"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"M Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.exphem.2007.01.023","article-title":"Optimizing therapy of chronic myeloid leukemia.","volume":"35","author":"MW Deininger","year":"2007","journal-title":"Exp Hematol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.","volume":"7","author":"E Weisberg","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.","volume":"8","author":"JF Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.","volume":"354","author":"H Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.","volume":"110","author":"U Rix","year":"2007","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.leukres.2007.11.008","article-title":"Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.","volume":"32","author":"Y Deguchi","year":"2008","journal-title":"Leuk Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2006-07-035493","article-title":"Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.","volume":"109","author":"A Quintas-Cardama","year":"2007","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"18292","DOI":"10.1074\/jbc.M801337200","article-title":"Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib\/nilotinib and dasatinib.","volume":"283","author":"N Vajpai","year":"2008","journal-title":"J Biol Chem"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/10428190801896103","article-title":"Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.","volume":"49","author":"O Hantschel","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2006-06-026377","article-title":"Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.","volume":"109","author":"E Weisberg","year":"2007","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.","volume":"110","author":"T O'Hare","year":"2007","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.","volume":"109","author":"FJ Giles","year":"2007","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1747-0285.2007.00556.x","article-title":"Crystal structure of the T315I mutant of AbI kinase.","volume":"70","author":"T Zhou","year":"2007","journal-title":"Chem Biol Drug Des"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1158\/0008-5472.CAN-07-1825","article-title":"Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.","volume":"67","author":"M Modugno","year":"2007","journal-title":"Cancer Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","article-title":"Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.","volume":"111","author":"A Gontarewicz","year":"2008","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.","volume":"463","author":"J Zhang","year":"2010","journal-title":"Nature"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-642-01222-8_14","article-title":"Danusertib (formerly PHA-739358) - A Novel Combined Pan-Aurora Kinases and Third Generation Bcr-Abl Tyrosine Kinase Inhibitor.","volume":"184","author":"A Gontarewicz","year":"2010","journal-title":"Recent Results Cancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2174\/156802608784911635","article-title":"Inhibitors of ABL and the ABL-T315I mutation.","volume":"8","author":"G Noronha","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"ref36","first-page":"1727","article-title":"A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.","volume":"63","author":"JH Goldie","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0025-5564(83)90066-4","article-title":"A model for resistance of tumor cells to cancer chemotherapeutic agents.","volume":"65","author":"JH Goldie","year":"1983","journal-title":"Mathematical Biosciences"},{"key":"ref38","first-page":"923","article-title":"Quantitative model for multiple levels of drug resistance in clinical tumors.","volume":"67","author":"JH Goldie","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"ref39","first-page":"1041","article-title":"Role of mathematical modeling in protocol formulation in cancer chemotherapy.","volume":"69","author":"AJ Coldman","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF02459682","article-title":"A stochastic model for the origin and treatment of tumors containing drug-resistant cells.","volume":"48","author":"AJ Coldman","year":"1986","journal-title":"Bull Math Biol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/jnci\/66.6.1037","article-title":"Mutation and cancer: a model for human carcinogenesis.","volume":"66","author":"SH Moolgavkar","year":"1981","journal-title":"J Natl Cancer Inst"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1539-6924.1988.tb00502.x","article-title":"A stochastic two-stage model for cancer risk assessment. I. The hazard function and the probability of tumor.","volume":"8","author":"SH Moolgavkar","year":"1988","journal-title":"Risk Anal"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF00118413","article-title":"A two-stage carcinogenesis model for risk assessment.","volume":"5","author":"SH Moolgavkar","year":"1989","journal-title":"Cell Biol Toxicol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/genetics\/125.3.633","article-title":"Mathematical models of gene amplification with applications to cellular drug resistance and tumorigenicity.","volume":"125","author":"M Kimmel","year":"1990","journal-title":"Genetics"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF02460646","article-title":"Time-continuous branching walk models of unstable gene amplification.","volume":"56","author":"M Kimmel","year":"1994","journal-title":"Bull Math Biol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0025-5564(91)90094-Y","article-title":"The dynamics of gene amplification described as a multitype compartmental model and as a branching process.","volume":"103","author":"LE Harnevo","year":"1991","journal-title":"Math Biosci"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0165-1161(93)90004-J","article-title":"Use of mathematical models for understanding the dynamics of gene amplification.","volume":"292","author":"LE Harnevo","year":"1993","journal-title":"Mutat Res"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00109-007-0241-y","article-title":"Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia\u2013insights from mathematical model analyses.","volume":"86","author":"I Roeder","year":"2008","journal-title":"J Mol Med"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0025-5564(92)90053-Y","article-title":"A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs.","volume":"109","author":"L Cojocaru","year":"1992","journal-title":"Math Biosci"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.bulm.2004.09.002","article-title":"The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics.","volume":"67","author":"EA Gaffney","year":"2005","journal-title":"Bull Math Biol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00285-003-0246-2","article-title":"The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling.","volume":"48","author":"EA Gaffney","year":"2004","journal-title":"J Math Biol"},{"key":"ref52","first-page":"1079","article-title":"New tools for cancer chemotherapy: computational assistance for tailoring treatments.","volume":"2","author":"SN Gardner","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0025-5564(99)00062-0","article-title":"A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy.","volume":"164","author":"TL Jackson","year":"2000","journal-title":"Math Biosci"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0025-5564(94)00117-3","article-title":"Growth of nonnecrotic tumors in the presence and absence of inhibitors.","volume":"130","author":"HM Byrne","year":"1995","journal-title":"Math Biosci"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/jnci\/86.15.1152","article-title":"Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis.","volume":"86","author":"JP Jaffrezou","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4899-5037-6_1","article-title":"Genomic instability, tumor heterogeneity and progression.","volume":"233","author":"WS Kendal","year":"1988","journal-title":"Adv Exp Med Biol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2174\/138161206775201956","article-title":"Evolution of resistance to cancer therapy.","volume":"12","author":"F Michor","year":"2006","journal-title":"Curr Pharm Des"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.mbs.2006.05.003","article-title":"Chemotherapy for tumors: an analysis of the dynamics and a study of quadratic and linear optimal controls.","volume":"209","author":"LG de Pillis","year":"2007","journal-title":"Math Biosci"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"9714","DOI":"10.1073\/pnas.0501870102","article-title":"Drug resistance in cancer: principles of emergence and prevention.","volume":"102","author":"NL Komarova","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"e4423","DOI":"10.1371\/journal.pone.0004423","article-title":"Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia.","volume":"4","author":"NL Komarova","year":"2009","journal-title":"PLoS One"},{"key":"ref61","article-title":"Mathematical modeling of drug cross-resistance in cancer.","author":"AA Katouli","year":"2009"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.tpb.2007.08.003","article-title":"Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer.","volume":"72","author":"NL Komarova","year":"2007","journal-title":"Theor Popul Biol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.1371\/journal.pone.0000990","article-title":"Effect of Cellular Quiescence on the Success of Targeted CML Therapy.","volume":"2","author":"NL Komarova","year":"2007","journal-title":"PLoS ONE"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jtbi.2005.08.003","article-title":"Stochastic modeling of drug resistance in cancer.","volume":"239","author":"N Komarova","year":"2006","journal-title":"J Theor Biol"},{"key":"ref65","author":"RG McKinnell","year":"1998"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"S Branford","year":"2009","journal-title":"Blood"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants.","volume":"27","author":"S Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1158\/1078-0432.CCR-09-1445","article-title":"A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.","volume":"15","author":"RB Cohen","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0012300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T02:02:28Z","timestamp":1636250548000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0012300"}},"subtitle":[],"editor":[{"given":"Roger","family":"Chammas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,8,23]]},"references-count":68,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2010,8,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0012300","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,23]]}}}